Biodexa Pharmaceuticals Plc (BDRX)

Biodexa Pharmaceuticals Balance Sheet

Financials in millions GBP. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	5.97	2.84	10.06	7.55	10.93
Cash & Cash Equivalents	5.97	2.84	10.06	7.55	10.93
Cash Growth	110.54%	-71.80%	33.28%	-30.95%	366.41%
Receivables	0.64	1.01	1.03	0.57	3.62
Other Current Assets	0.42	0.85	0.67	1.16	-0.81
Total Current Assets	7.03	4.69	11.76	9.28	13.74
Property, Plant & Equipment	0.57	0.83	1.15	0.54	2.15
Goodwill and Intangibles	2.94	0.01	0	0	12.38
Other Long-Term Assets	0	0	0	0	2.63
Total Long-Term Assets	3.51	0.84	1.15	0.54	17.16
Total Assets	10.54	5.53	12.91	9.82	30.9
Accounts Payable	1.24	1.45	1.09	1.23	4.49
Current Debt	0.17	0.16	0.15	0.2	0.41
Other Current Liabilities	4.16	0.29	0.6	1.56	0.76
Total Current Liabilities	5.57	1.9	1.84	2.99	5.67
Long-Term Debt	0.3	0.46	0.62	0.06	5.67
Other Long-Term Liabilities	0	0	0	0.05	0
Total Long-Term Liabilities	0.3	0.46	0.62	0.11	5.67
Total Liabilities	5.86	2.36	2.46	3.1	11.34
Total Debt	0.46	0.62	0.77	0.26	6.08
Debt Growth	-25.64%	-18.54%	194.62%	-95.73%	385.78%
Retained Earnings	-144.77	-135.34	-127.8	-122.43	-99.84
Comprehensive Income	0	0	0	0	-0.51
Shareholders' Equity	4.68	3.16	10.45	6.72	19.56
Net Cash / Debt	5.51	2.21	9.29	7.29	4.85
Net Cash / Debt Growth	148.96%	-76.19%	27.52%	50.35%	344.18%
Working Capital	1.46	2.79	9.92	6.29	8.07
Book Value Per Share	6.73	256.83	1325.68	1969.82	12786.32

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).